Loading...

Table of Content

    20 May 2026, Volume 41 Issue 5
    Meta-analysis of the effects of exercise on sleep quality intervention in Chinese adolescents with sleep disorders
    Liu Dongfei, Jiang Yucheng, Wang Zhanfeng
    2026, 41(5):  389-398.  doi:10.3969/j.issn.1004-583X.2026.05.001
    Asbtract ( 25 )   PDF (1573KB) ( 11 )   HTML ( 1)  
    Figures and Tables | References | Related Articles | Metrics

    Objective To systematically evaluate the effects of exercise intervention on sleep quality in Chinese adolescents with sleep disorders and provide evidence-based support for the treatment of adolescent sleep disorders. Methods Databases including CNKI, VIP, Wanfang, China Biology Medicine disc, Web of Science, PubMed, Cochrane Library, and Embase were searched from inception to June 10, 2025. Literature screening was performed according to the PICOS principle (Population, Intervention, Comparison, Outcome, Study design). Ultimately, 26 articles involving 34 studies were included. The Cochrane risk-of-bias tool was used to assess study quality, and state18.0 and RevMan 5.4 were used for statistical analysis and publication bias testing. Results A total of 34 studies with 2, 007 participants were included, including 1, 016 in the experimental group and 991 in the control group. The meta-analysis showed that exercise intervention had a statistically significant effect on improving sleep quality in adolescents with sleep disorders (SMD=-1.19, 95%CI[-1.45, -0.92], P<0.01). Subgroup analysis showed that aerobic dance, high-intensity exercise interventions, a frequency of 5 or more sessions per week, exercise duration longer than 60 min, and an intervention period of 4-8 weeks produced the largest effect sizes in adolescents in Central China with sleep disorder severity at or above a moderate level (P<0.01). Conclusion Exercise intervention has a significant effect on improving sleep quality in Chinese adolescents with sleep disorders and may serve as an important non-pharmacological treatment in the future clinical management of sleep disorders.

    Relationship between serum FABP5, SII, and VEGF levels and prognosis in patients with liver cancer
    Wang Tianhui, Lyu Hui, Feng Lifei, Chen Yajie
    2026, 41(5):  399-405.  doi:10.3969/j.issn.1004-583X.2026.05.002
    Asbtract ( 22 )   PDF (1044KB) ( 7 )   HTML ( 0)  
    Figures and Tables | References | Related Articles | Metrics

    Objective To investigate the relationship between serum fatty acid binding protein 5 (FABP5), systemic immune inflammatory index (SII), vascular endothelial growth factor (VEGF) levels, and prognosis in patients with liver cancer. Methods A total of 200 patients with liver cancer admitted to Anyang General Hospital and Anyang Cancer Hospital from March 2021 to March 2024 were retrospectively enrolled as the observation group. In addition, 200 patients with cirrhosis or chronic hepatitis during the same period were selected as the control group. Clinical data were collected and serum FABP5, SII, and VEGF levels were compared between the two groups. Patients in the observation group were followed up for 1 year after treatment, and prognostic outcomes were recorded. Patients with metastasis, recurrence, or death were assigned to the poor prognosis group (n=94), whereas patients with stable or improved disease were assigned to the good prognosis group (n=106). Serum FABP5, SII, and VEGF levels were compared between the two prognostic groups. Multivariate Cox regression analysis was used to identify risk factors affecting prognosis in patients with liver cancer. The receiver operating curve (ROC) was used to evaluate the predictive performance of serum FABP5, SII, and VEGF for prognosis in patients with liver cancer. Results Serum FABP5 ([14.51±3.41]μg/L), SII (323.45±31.52), and VEGF ([381.52±40.56] ng/L) levels in the observation group were all higher than those in the control group ([7.85±2.86] μg/L, [198.64±25.68], and [205.64±27.86] ng/L, respectively), with statistically significant differences (P<0.05). The proportion of patients with TNM stage Ⅰ-Ⅱ disease was 72.64% in the good prognosis group, which was higher than 31.91% in the poor prognosis group. Serum alpha-fetoprotein (AFP) ([277.65±36.53]μg/L], PIVKA-Ⅱ ([315.68±58.64]μg/L), FABP5 ([11.33±2.86] μg/L), SII (291.64±36.45), and VEGF ([316.53±38.49] ng/L) levels were lower than those in the poor prognosis group ([291.47±40.37] μg/L, [336.55±62.49] μg/L, [17.85±2.68]μg/L, [342.56±40.15], and [457.68±52.11] ng/L, respectively), with statistically significant differences (P<0.05). Serum FABP5 ([15.48±3.05]μg/L), SII (349.56±43.97), and VEGF ([429.68±66.54] ng/L) levels in patients with TNM stage Ⅲ-Ⅳ disease were significantly higher than those in patients with stage Ⅰ-Ⅱ disease (FABP5 [13.50±2.61]μg/L, SII [281.68±38.67], and VEGF [320.45±55.18] ng/L). In addition, within the TNM stage Ⅰ-Ⅱ and Ⅲ-Ⅳ subgroups, serum FABP5, SII, VEGF, AFP, and PIVKA-Ⅱ levels were all significantly higher in the poor prognosis group than in the good prognosis group, with statistically significant differences (all P<0.05). The area under the curve (AUC) for combined prediction of prognosis using serum FABP5, SII, and VEGF was 0.879, which was higher than the individual AUC values for each marker (0.637, 0.534, and 0.619, respectively). The AUC for combined prediction using serum AFP and PIVKA-Ⅱ was 0.835, indicating better predictive performance for the combined serum FABP5, SII, and VEGF model. Cox regression analysis showed that FABP5≥14.96 μg/L, SII≥308.00, VEGF≥380.72 ng/L, and TNM stage Ⅲ-Ⅳ were risk factors for prognosis in patients with liver cancer (P<0.05). Conclusion Serum FABP5, SII, and VEGF are specifically elevated in patients with liver cancer, and their levels are significantly associated with prognosis.

    Distribution of uropathogens in patients with malignant tumors and the application of combined blood glucose and urinalysis testing
    Shi Shaoxin, Chen Xueting, Zhuang Yihui, Guo Lin, Lu Renquan, Xu Xiaofeng
    2026, 41(5):  406-410.  doi:10.3969/j.issn.1004-583X.2026.05.003
    Asbtract ( 17 )   PDF (474KB) ( 1 )   HTML ( 2)  
    Figures and Tables | References | Related Articles | Metrics

    Objective To investigate the distribution of uropathogens in patients with urinary tract infection (UTI) and malignant tumors, and to evaluate the diagnostic value of combined urinalysis indices and fasting blood glucose for UTI in this population, providing a reference for early clinical diagnosis. Methods Hospitalized patients with malignant tumors admitted to Fudan University Shanghai Cancer Center from January 2024 to June 2025 were included. Among them, 264 patients with positive urine cultures were assigned to the positive group, and 273 patients with negative urine cultures were assigned to the control group. Urinalysis indices, including nitrite (NIT), leukocyte esterase (LEU), urine white blood cell count (UWBC), urine glucose, and fasting blood glucose, were measured in all participants. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic performance of each indicator and their combined model for UTI. Results A total of 265 pathogens were isolated from the positive group. Gram-negative bacteria accounted for 75.85%, and Gram-positive bacteria accounted for 24.15%. The positive rates of NIT, LEU, urine glucose, UWBC, and the blood glucose level were significantly higher in the positive group than in the control group (P<0.05). ROC curve analysis showed that the area under the curve (AUC) for NIT, LEU, UWBC, and blood glucose in the diagnosis of UTI was 0.637, 0.700, 0.733, and 0.655, respectively. The AUC for the combined detection of these 4 indicators was 0.805, with a sensitivity of 75.00% and a specificity of 77.29%. Conclusion In patients with malignant tumors, the combined detection of urinalysis indices (NIT, LEU, UWBC) and fasting blood glucose has good auxiliary diagnostic value for UTI. Its diagnostic performance is superior to that of individual indicators and may provide a useful reference for early risk assessment and anti-infective decision-making before urine culture results become available.

    Artificial intelligence-assisted assessment of BI-RADS category 4 breast nodules by physicians of different seniority
    Liu Xiaoli, Yang Shuang, Yin Li, Hu Yan, Zheng Yumeng, Duan Lihong
    2026, 41(5):  411-416.  doi:10.3969/j.issn.1004-583X.2026.05.004
    Asbtract ( 20 )   PDF (626KB) ( 6 )   HTML ( 0)  
    Figures and Tables | References | Related Articles | Metrics

    Objective To evaluate the diagnostic performance of a deep learning model based on YOLOv5 in assisting ultrasound physicians with different levels of experience in diagnosing breast imaging reporting and data system (BI-RADS) category 4 breast nodules. Methods A total of 100 patients with suspicious breast malignant lesions who underwent breast ultrasonography at Affiliated Zhongshan Hospital of Dalian University from August 2023 to October 2024 were included, yielding 135 nodules. According to the ultrasonographic (US) BI-RADS classification, and with histopathology as the reference standard, three ultrasound physicians with different seniority levels and an artificial intelligence model independently assessed the benignity or malignancy of the nodules. The diagnostic performance of physicians of different seniority levels, with and without assistance from the artificial intelligence model, was then analyzed. Results Among the 135 nodules, 76 were classified as BI-RADS 4A, 41 as 4B, and 18 as 4C; histopathology confirmed 57 malignant nodules and 78 benign nodules. Using histopathological findings as the reference standard, the YOLOv5 model achieved higher sensitivity, specificity, accuracy, and AUC than the low-seniority physicians, with statistically significant differences (P<0.05). Its sensitivity and accuracy were lower than those of the high-seniority and mid-seniority physicians, with statistically significant differences (P<0.05). After combining the YOLOv5 model with physicians of different seniority levels, the low-seniority group showed an increase in sensitivity from 64.91% to 80.70%, accuracy from 65.18% to 74.81%, specificity from 65.38% to 70.51%, and AUC from 0.618 to 0.782 (P<0.001). In the mid-seniority group, sensitivity increased from 80.70% to 91.22%, accuracy from 77.03% to 80.74%, and AUC from 0.767 to 0.872 (P=0.013). In the high-seniority group, no statistically significant differences were observed in sensitivity, accuracy, specificity, or AUC (P=0.679). Subtype analysis showed that the combined approach was most effective for BI-RADS 4A nodules. In the low-seniority group, diagnostic accuracy for 4A nodules increased from 59.21% to 71.05%; in the mid-seniority group, it increased from 73.68% to 82.89%. Conclusion The YOLOv5 deep learning model can significantly improve the differential diagnostic ability of low- and mid-seniority physicians for BI-RADS category 4 breast nodules, with the greatest added value for 4A nodules. This approach may help reduce unnecessary biopsy and surgery.

    Current status and related factors of complications after CT-guided lung biopsy
    Min Huidong, Li Guangqing, Zheng Kun
    2026, 41(5):  417-422.  doi:10.3969/j.issn.1004-583X.2026.05.005
    Asbtract ( 23 )   PDF (897KB) ( 3 )   HTML ( 1)  
    Figures and Tables | References | Related Articles | Metrics

    Objective To investigate the current status of complications after computer tomography (CT)-guided lung biopsy and identify related factors. Methods This retrospective study collected clinical data from 184 patients who underwent elective CT-guided lung biopsy at Guangshan County People’s Hospital from March 2023 to March 2025. No patients were lost to follow-up during the study period. Postoperative complications were recorded. Patients were grouped according to the occurrence of postoperative pneumothorax or bleeding, and basic patient characteristics were collected to evaluate the factors influencing postoperative pneumothorax and bleeding after CT-guided lung biopsy. Results Among the 184 patients, 79 developed postoperative complications, with an overall complication rate of 42.93%. These included 45 cases of pneumothorax (24.46%), 38 cases of bleeding-related complications (20.65%), 5 cases of pleural reaction (2.72%), and 10 cases of puncture-site infection (5.43%). Multivariate logistic regression analysis showed that needle length through lung tissue, comorbid chronic obstructive pulmonary disease, lesion maximum diameter ≤20 mm, preoperative residual volume/total lung capacity ratio (RV/TLC%), preoperative forced vital capacity (FVC), forced expiratory volume in 1 second as a percentage of predicted value (FEV1%), and peak expiratory flow (PEF) were all independent risk factors for postoperative pneumothorax (P<0.05). Lesion maximum diameter ≤20 mm, needle length through lung tissue, puncture needle angle with the pleura <40°, and preoperative diffusing capacity for carbon monoxide as a percentage of predicted value (DLCO%) were independent risk factors for postoperative bleeding after CT-guided lung biopsy (P<0.05). Conclusion Postoperative complications such as pneumothorax and bleeding are relatively common after CT-guided lung biopsy. Comorbid chronic obstructive pulmonary disease, lesion maximum diameter ≤20 mm, needle length through lung tissue, and low preoperative pulmonary function parameters (FVC, FEV1%, PEF, RV/TLC%) are the main factors associated with postoperative pneumothorax. In contrast, lesion maximum diameter ≤20 mm, puncture needle angle with the pleura <40°, needle length through lung tissue, and high preoperative DLCO% are the main factors associated with postoperative bleeding. Targeted interventions based on these risk factors may help reduce postoperative complication risk and improve prognosis.

    Clinical manifestations and prognostic factors of severe pneumonia in infants and young children
    He Yanxiang, Wang Hao
    2026, 41(5):  423-428.  doi:10.3969/j.issn.1004-583X.2026.05.006
    Asbtract ( 21 )   PDF (909KB) ( 1 )   HTML ( 0)  
    Figures and Tables | References | Related Articles | Metrics

    Objective To analyze the clinical manifestations and prognostic factors of severe pneumonia in infants and young children, and to provide a reference for clinical diagnosis and treatment. Methods Clinical data of 304 infants and young children with severe pneumonia admitted to our hospital from November 2021 to November 2025 were collected, and their clinical characteristics were summarized. According to the 1-month post-discharge follow-up results, the children were divided into a good prognosis group (n=256) and a poor prognosis group (n=48). General information, use of mechanical ventilation, mixed infection, and the occurrence of complications (heart failure and respiratory failure) were compared between the two groups. Multivariate logistic regression analysis was used to identify factors associated with poor prognosis in infants and young children with severe pneumonia. Results Among the 304 children, 54.61% (166/304) were male, the mean age was (1.42±0.41) years, and 24.34% (74/304) were preterm at birth. Pathogenic specimens were detected in 268 cases, with a detection rate of 88.16%. Viral infection was the main pathogen type (46.05%). Mixed infection accounted for 19.08% (58/304), with virus-bacteria mixed infection being the most common (68.97%). The main clinical manifestations were fever (82.89%, 252/304), cough (92.76%, 282/304), shortness of breath (88.82%, 270/304), nasal flaring (67.11%, 204/304), and three-concave sign (64.47%, 196/304). The incidence of convulsions was 11.84% (36/304), and poor appetite was 61.18% (186/304). The main complications were respiratory failure (27.0%, 82/304) and heart failure (20.39%, 62/304). Compared with the good prognosis group, children in the poor prognosis group were younger, had lower birth weight, had a higher proportion of preterm birth, and showed higher rates of mechanical ventilation use, mixed infection, concomitant heart failure, and respiratory failure (P<0.05). Multivariate logistic regression analysis showed that concomitant heart failure and concomitant respiratory failure were independent risk factors for poor prognosis in infants and young children with severe pneumonia (P<0.05). Conclusion Severe pneumonia in infants and young children presents with diverse clinical manifestations, mainly respiratory symptoms and systemic inflammatory responses. Concomitant heart failure or respiratory failure increases the risk of poor prognosis.

    Clinical phenotypic characteristics and gene mutation spectrum analysis of inherited metabolic diseases in neonates presenting with gastrointestinal symptoms
    Liu Xinyu, He Rugu, Cui Qingyang
    2026, 41(5):  429-440.  doi:10.3969/j.issn.1004-583X.2026.05.007
    Asbtract ( 19 )   PDF (1052KB) ( 4 )   HTML ( 0)  
    Figures and Tables | References | Related Articles | Metrics

    Objective To summarize the clinical phenotypes and genotypes of inherited metabolic diseases in neonates presenting with gastrointestinal symptoms. Methods A retrospective review was conducted of clinical data from children admitted to the Department of Neonatology of the First Affiliated Hospital of Henan Medical University and the Department of Neonatology of Gushi County Maternal and Child Health Hospital from November 2017 to November 2025. The included children presented with gastrointestinal symptoms as the initial manifestation, were initially suspected of having inherited metabolic diseases, and underwent genetic testing. Collected data included sex, age, clinical phenotype, and genetic testing results. Results Among the 429 children included, 196 had abnormal genetic results, yielding a positive rate of 45.69%; 105 were male and 91 were female. The main clinical manifestations were jaundice in 84.19%, cholestasis in 10.71%, feeding difficulty in 5.61%, hepatomegaly in 2.55%, vomiting in 2.04%, and diarrhea in 0.51%. The major disease phenotypes were as follows: ①Hereditary non-hemolytic unconjugated hyperbilirubinemia in 139 cases (37 with Gilbert syndrome and 102 with Crigler-Najjar syndrome type II), with clinical manifestations of jaundice and elevated unconjugated bilirubin. Eighteen UGT1A1 mutation types were identified, and the top five mutations were c.211G>A, c.1091C>T, c.-41_-40dup, c.-3275T>G, and c.1456T>G, accounting for 92.20% of all mutations. ②Sodium taurocholate cotransporting polypeptide deficiency in 11 cases, all presenting with jaundice and delayed resolution of jaundice; c.800C>T was the most common variant, with an allelic frequency of 90.90%. ③Alagille syndrome in 9 cases, all presenting with skin and scleral jaundice; 1 case also had hepatomegaly. Among them, 4 cases had type I JAG1 mutations and 5 cases had type Ⅱ NOTCH2 mutations. ④Citrin deficiency-associated neonatal intrahepatic cholestasis in 7 cases, with 2 frameshift mutations detected, c.852_855del and c.1638_1660dup, accounting for allelic frequencies of 71.43% and 28.57%, respectively. ⑤Ornithine transcarbamylase deficiency in 6 cases, all with heterozygous OTC mutations, mainly presenting with feeding difficulty and hyperammonemia; 2 cases also had jaundice and 1 had marked hepatomegaly, and the prognosis was poor in all cases. ⑥Glucose-6-phosphate dehydrogenase deficiency in 5 cases, all presenting with skin and scleral jaundice and hemolytic manifestations; all were hemizygous G6PD mutations in male infants. ⑦Very long-chain acyl-CoA dehydrogenase deficiency in 3 cases, all with homozygous ACADVL mutations and mainly presenting with vomiting and feeding difficulty. The mutations c.1843C>T (2 cases) and c.1078-1G>A (1 case) were identified. ⑧Cystic fibrosis in 3 cases, mostly presenting with jaundice and cholestasis, all compound heterozygous CFTR mutations. ⑨Wilson disease in 3 cases, all presenting with jaundice and compound heterozygous ATP7B mutations. ⑩Microvillus inclusion disease in 2 cases, both with compound heterozygous MYO5B mutations. 11Hereditary spherocytosis in 8 cases, all initially presenting with recurrent severe jaundice, mostly accompanied by severe anemia. These included 1 case of type 1 hereditary spherocytosis (ANK1), 2 cases of type 2 (SPTB), 1 case of type 3 (SPTA1), 2 cases of type 4 (SLC4A1), 1 case of type 5 (SLC4A1), and 1 case of type 1 combined with type 5 (EPB42). 12One case of Dubin-Johnson syndrome combined with Gilbert syndrome, presenting with jaundice and an ABCC2 heterozygous mutation. 13One case of Rotor syndrome, presenting with jaundice and elevated direct bilirubin, with compound heterozygous SLCO1B3 mutations. 14One case of galactosemia, with compound heterozygous GALT mutations. 15One case of citrullinemia type I, presenting with feeding difficulty and hepatomegaly, with compound heterozygous ASS1 mutations.16 One case of congenital bile acid synthesis disorder type 3, presenting with jaundice, elevated liver enzymes, and cholestasis, with a homozygous CYP7B1 mutation. 17One case of progressive familial intrahepatic cholestasis type 1, with compound heterozygous ATP8B1 mutations. 18One case of very early-onset inflammatory bowel disease combined with Gilbert syndrome, with vomiting, diarrhea, feeding difficulty, and decreased bowel sounds as the main manifestations, and a heterozygous mutation at PLGC2 c.3670C>T. Conclusion This study confirms the high diagnostic value of genetic testing in neonates presenting with gastrointestinal symptoms. It systematically elucidates the disease spectrum and mutation characteristics of inherited metabolic diseases in this population, providing important data support for the development of efficient clinical diagnostic pathways, individualized treatment, and genetic counseling.

    Serum sST2 levels in children with Mycoplasma pneumoniae pneumonia complicated by Epstein-Barr virus infection and their correlation with clinical indicators
    Ye Qi, Wang Yingying, Qiu Xin, Chen Wenke, Cao Longbin
    2026, 41(5):  441-446.  doi:10.3969/j.issn.1004-583X.2026.05.008
    Asbtract ( 20 )   PDF (1135KB) ( 4 )   HTML ( 1)  
    Figures and Tables | References | Related Articles | Metrics

    Objective To investigate the level of soluble suppression of tumorigenicity 2 (sST2) in children with Mycoplasma pneumoniae pneumonia (MPP) complicated by Epstein-Barr virus (EBV) infection, and to assess its correlations with clinical indicators, thereby evaluating its potential value in determining disease severity. Methods Clinical data were retrospectively analyzed for 69 children with MPP complicated by EBV infection (MP+EB group), 77 children with Mycoplasma pneumoniae infection alone (MP group), and 70 healthy children who underwent physical examination during the same period (HC group), all hospitalized in the Department of Pediatrics of the Seventh Affiliated Hospital of Southern Medical University from April 2024 to February 2025. Serum sST2 and laboratory indicators of inflammation, myocardial injury, and liver function were measured. Spearman correlation analysis was used to evaluate the correlations between sST2 and these indicators. Results Serum sST2 levels were higher in the MP+EB group than in the MP group and HC group (P<0.01), and were also higher in the MP group than in the HC group (P<0.05). The MP+EB group had longer fever duration, longer hospital stay, and higher C-reactive protein (CRP) and lactate dehydrogenase (LDH) levels than the MP group (P<0.05), but there was no statistically significant difference in procalcitonin (PCT) levels between the two groups (P>0.05). In the MP+EB group, sST2 was positively correlated with CRP, dydroxybutyrate dehydrogenase, LDH, high-sensitivity C-reactive protein (hs-CRP), aspartate aminotransferase (AST), and creatine kinase-MB (CK-MB) (rs=0.805, 0.792, 0.806, 0.768, 0.394, and 0.523, respectively; all P<0.01), but showed no correlation with PCT (rs=0.133, P=0.276). In the MP group, sST2 was also positively correlated with the above indicators and was additionally positively correlated with PCT (rs=0.646, P<0.01). Conclusion Serum sST2 is elevated in children with MPP complicated by EBV infection and is closely associated with inflammation, myocardial injury, and tissue injury markers. These findings suggest that sST2 may serve as a potential biomarker for assessing disease severity in these patients, and that its elevation may be related to immune-inflammatory pathways triggered by viral infection.

    Systemic lupus erythematosus complicated by acute liver failure: A case report
    Lyu Peizhen, Cui Chengjie, Fu Na, Nan Yuemin
    2026, 41(5):  447-451.  doi:10.3969/j.issn.1004-583X.2026.05.009
    Asbtract ( 19 )   PDF (1179KB) ( 4 )   HTML ( 0)  
    Figures and Tables | References | Related Articles | Metrics

    Objective To analyze a case of systemic lupus erythematosus (SLE) presenting initially as acute liver failure (ALF), and to explore its clinical features, diagnostic and therapeutic approach, and key points for differential diagnosis. Methods The clinical data of a patient with SLE complicated by ALF were retrospectively reviewed, and relevant literature was also summarized. Results The patient was a 17-year-old woman admitted with a 1-week history of nausea, fatigue, poor appetite, jaundice, and dark urine. Coagulation testing showed a prothrombin time activity (PTA) of 38% and an international normalized ratio (INR) of 1.96, accompanied by grade II hepatic encephalopathy, meeting the diagnostic criteria for ALF. Immunological tests revealed antinuclear antibody (ANA) 1:3 200, positive anti-dsDNA, decreased complement C3 and C4, positive anticardiolipin antibody, and elevated 24-h urine protein. After plasma exchange combined with methylprednisolone pulse therapy, human immunoglobulin, hydroxychloroquine, and tacrolimus treatment, the patient’s liver function and coagulation function improved significantly, and her condition became stable. Conclusion In young women with unexplained ALF, SLE-related autoantibodies should be screened as early as possible to clarify the etiology, avoid misdiagnosis or missed diagnosis, and improve prognosis.

    Sarcoidosis complicated by minimal change glomerulopathy: A case report and literature review
    Yu Baisong, Dong Chunxia, Hu Zhijuan, Liu Bing
    2026, 41(5):  452-456.  doi:10.3969/j.issn.1004-583X.2026.05.010
    Asbtract ( 17 )   PDF (995KB) ( 2 )   HTML ( 1)  
    Figures and Tables | References | Related Articles | Metrics

    Objective To investigate the pathogenesis, diagnosis, and treatment of sarcoidosis complicated by minimal change glomerulopathy. Methods We retrospectively analyzed the diagnosis and treatment of one case of sarcoidosis complicated by minimal change glomerulopathy and reviewed the relevant literature from China and abroad. Results We report a 72-year-old woman who was diagnosed with sarcoidosis 2 years earlier and had previously received treatment with methylprednisolone, leflunomide, and tripterygium glycosides. She was admitted because of edema of the lower extremities, massive proteinuria, and hypoalbuminemia. After admission, renal biopsy confirmed minimal change glomerulopathy complicated by acute tubular necrosis. Methylprednisolone was initially administered at 80 mg once daily, and the dose was later adjusted to 48 mg once daily. After systematic treatment, the patient’s renal function recovered and nephrotic syndrome achieved complete remission. The glucocorticoid dose was gradually tapered, and no recurrence of nephrotic syndrome was observed during follow-up. Conclusion This case is one of the few reported cases of sarcoidosis complicated by isolated minimal change glomerulopathy and responsive to glucocorticoid therapy. The findings may provide new insights into the etiology and potential immune mechanisms of sarcoidosis complicated byminimal change glomerulopathy.